Neoantigen × AI
Daily research signal
№46Brief

Intismeran cuts melanoma recurrence risk 42% in phase 3

Today's signal is the first full phase 3 readout for an individualized neoantigen therapy: Merck and Moderna's intismeran autogene cut recurrence risk 42% in resected stage IIB-IV melanoma when added to pembrolizumab.The American Journal of Managed Care

That is the strongest clinical validation to date for the patient-specific neoantigen vaccine modality, and the market is already repricing the platform, with Moderna up over 600% this year on the strength of its cancer vaccine program.The American Journal of Managed CareNAI500 Together, the items mark neoantigen vaccines moving from platform promise toward adjuvant-standard contender.

2new stories
CommercialtodayNew

Moderna Soars Over 600% This Year, Personalized Cancer Vaccine Becomes Key Catalyst - NAI500

Moderna shares have surged more than 600% this year, with the company's personalized cancer vaccine program cited as a key catalyst, according to NAI500. The rally signals investors are treating Moderna's oncology franchise as a material growth driver rather than a side bet alongside its respiratory portfolio. With the full phase 3 INTerpath-001 data for the Merck-partnered intismeran autogene now public, the commercial narrative behind the stock's run has a concrete clinical anchor.

news · today · NAI500

01

01
Clinicallast weekNew

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% - The American Journal of Managed Care

Full results from phase 3 INTerpath-001 (NCT05933577) show Merck and Moderna's intismeran autogene (V940; mRNA-4157), an individualized mRNA neoantigen therapy, reduced the risk of recurrence or death by 42% versus pembrolizumab alone in patients with completely resected stage IIB-IV melanoma. Principal investigator Professor Georgina Long of Melanoma Institute Australia framed the findings as a potential foundational shift in adjuvant treatment of earlier-stage melanoma, tailoring therapy to each patient's tumor rather than its anatomic origin. The readout is the field's clearest phase 3-level evidence that patient-specific neoantigen targeting can deliver clinical benefit at scale, a de-risking moment for the broader individualized cancer vaccine category.

news · last week · The American Journal of Managed Care